Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2013
06/13/2013WO2013085422A2 Antitubercular composition and method for producing same
06/13/2013WO2013085384A1 Methods for providing sialylated oligosaccharides
06/13/2013WO2013085352A1 Pharmaceutical composition comprising diaminodiphenylsulfone or the pharmaceutically acceptable salts thereof for preventing or treating diseases associated with decrease in bone mass
06/13/2013WO2013085351A1 Pharmaceutical composition comprising diaminodiphenylsulfone or the pharmaceutically acceptable salts thereof for preventing or treating diseases associated with muscle atrophy
06/13/2013WO2013085347A1 Novel phytosphingosine derivatives and cosmetic composition comprising same for preventing and improving inflammatory skin diseases and hyperkeratosis diseases
06/13/2013WO2013085346A1 Novel phytosphingosine derivatives, and composition comprising same for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratosis diseases
06/13/2013WO2013085340A1 Pharmaceutical composition comprising bicyclic pyridinol derivatives for preventing or treating diseases caused by angiogenesis
06/13/2013WO2013085338A2 Pharmaceutical composition for preventing and treating metabolic diseases, comprising nymphaea tetragona root extract, fractions thereof, or polyphenol-based compounds isolated from the nymphaea tetragona root extract as active ingredients
06/13/2013WO2013085276A1 Film for oral administration containing mirodenafil or pharmaceutically acceptable salt thereof
06/13/2013WO2013085224A1 Bitter taste masked oral thin film formulation of sildenafil citrate
06/13/2013WO2013085152A1 Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors
06/13/2013WO2013085018A1 Phenylpyrrole derivative
06/13/2013WO2013085017A1 Pyridone derivative and medicine containing same
06/13/2013WO2013085016A1 Pyridone derivative and medicine containing same
06/13/2013WO2013084995A1 Adhesive patch
06/13/2013WO2013084816A1 Agent for preventing and/or treating veisalgia
06/13/2013WO2013084532A1 Prophylactic or therapeutic agent for dysuria
06/13/2013WO2013084250A1 Combination of cyclophosphamide and dendritic cells for use in the treatment of uterine cervix carcinoma
06/13/2013WO2013084241A1 Compounds as inhibitors of renin
06/13/2013WO2013084238A1 Isolated stereoisomeric forms of (s) 2-n (3-o-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide
06/13/2013WO2013084237A1 Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
06/13/2013WO2013084216A2 Heteroaryl compounds and uses thereof
06/13/2013WO2013084210A1 Amorphous form of sitagliptin salts
06/13/2013WO2013084207A1 Formulations for micelle formation comprising a protein and methods preparation thereof
06/13/2013WO2013084199A1 Boron heterocycles as new inhibitors of human neutrophil elastase
06/13/2013WO2013084194A1 Topical pharmaceutical compositions of anti-microbial agents and anti-inflammatory agents
06/13/2013WO2013084191A1 Orodispersible sildenafil tablet and preparation method thereof
06/13/2013WO2013084182A1 Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
06/13/2013WO2013084165A1 Hcv polymerase inhibitors
06/13/2013WO2013084153A1 Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
06/13/2013WO2013084150A1 Novel crystal form of (2s)-2-amino-3-hydroxy-n-[2-methoxy-2-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof
06/13/2013WO2013084138A1 Cyclic urea derivatives as androgen receptor antagonists
06/13/2013WO2013084130A1 Multicomponent crystalline system of voriconazole with fumaric acid
06/13/2013WO2013084090A1 Oral liquid concentrate comprising brompheniramine, pseudoephedrine and dextromethorphan
06/13/2013WO2013084089A1 Methods for treating cardiovascular disorder
06/13/2013WO2013084061A1 Compositions for photodynamic therapy chemically modified to increase epithelia penetration and cellular bioavailability
06/13/2013WO2013084060A1 Quaternized buprenorphine analogs
06/13/2013WO2013084013A1 Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists
06/13/2013WO2013083994A1 Hydantoin derivatives useful as kv3 inhibitors
06/13/2013WO2013083991A1 Novel compounds and their use in therapy
06/13/2013WO2013083910A2 Topical emulsions based on mixtures of local eutectic anaesthetics and fatty acids as analgesics, antalgics, or as sexual retardants
06/13/2013WO2013083887A1 Novel association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide and an nmda receptor antagonist and the pharmaceutical compositions which contain said association
06/13/2013WO2013083867A1 Prevention and treatment of renal lesions associated with kidney stones in the urinary tract
06/13/2013WO2013083813A2 Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis
06/13/2013WO2013083809A1 Prevention of adverse effects caused by epcamxcd3 bispecific antibodies
06/13/2013WO2013083775A1 New compounds, pharmaceutical compositions and uses thereof
06/13/2013WO2013083741A1 1,2,4 -triazoles as allosteric modulators of mglu5 receptor activity for the treatment of schizophrenia of dementia
06/13/2013WO2013083724A1 Beta-o/s/n fatty acid based compounds as antibacterial and antiprotozoal agents
06/13/2013WO2013083685A1 Process for recovery of nalmefene hydrochloride
06/13/2013WO2013083674A1 Novel pharmaceutical statin composition
06/13/2013WO2013083666A1 Inhibitors of bruton's tyrosine kinase
06/13/2013WO2013083606A1 Kinase inhibitors
06/13/2013WO2013083604A1 Kinase inhibitors
06/13/2013WO2013083595A1 Antimicrobial composition
06/13/2013WO2013083594A1 Antimicrobial composition
06/13/2013WO2013083593A1 Antimicrobial composition
06/13/2013WO2013083592A1 Antimicrobial composition
06/13/2013WO2013083591A1 Substituted pyrazoles as mglu5 receptor modulators
06/13/2013WO2013083590A1 Method for disinfecting a surface
06/13/2013WO2013083588A1 Microbicidal composition
06/13/2013WO2013083587A1 Microbicidal composition
06/13/2013WO2013083585A1 Antimicrobial composition
06/13/2013WO2013083584A1 Antimicrobial composition
06/13/2013WO2013083583A1 Antimicrobial composition
06/13/2013WO2013083582A1 Antimicrobial composition
06/13/2013WO2013083581A1 Antimicrobial composition
06/13/2013WO2013083580A1 Microbicidal composition
06/13/2013WO2013083569A1 Nasal formulation
06/13/2013WO2013083568A1 6,7-dihydro-5h-benzo[7]annulene derivatives, methods for the production thereof, pharmaceutical preparations that contain said 6,7-dihydro-5h-benzo[7]annulene derivatives, and use thereof to produce drugs
06/13/2013WO2013083558A1 Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules
06/13/2013WO2013083557A1 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
06/13/2013WO2013083556A1 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
06/13/2013WO2013083553A1 Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
06/13/2013WO2013083552A1 Inhibition of cis-platin induced ototoxicity
06/13/2013WO2013083541A1 (4-mercapto-piperidin-4-yl)-aminoacetic acid derivatives, pharmaceutical compositions and uses thereof
06/13/2013WO2013083489A1 Metabolizable salts and use thereof in diagnostics and therapy
06/13/2013WO2013083286A1 TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
06/13/2013WO2013083225A1 Glucuronolactone derivates as self-tanning substances
06/13/2013WO2013083206A1 Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
06/13/2013WO2013083070A1 1, 4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof
06/13/2013WO2013083058A1 Platinum type compound with leaving group being hydroxy acid derivative containing amino group or alkyl amino, and preparation method and use thereof
06/13/2013WO2013083040A1 Application of fluoxetine to treatment of depigmentation diseases
06/13/2013WO2013083025A1 Composition used in manufacturing of medicaments for treatment of cerebrovascular diseases
06/13/2013WO2013083014A1 Daidzein derivative, pharmaceutically acceptable salt and preparation method thereof, and pharmaceutical composition containing same
06/13/2013WO2013082916A1 Strain of exopolysaccharide-secreting lactobacillus plantarum and application thereof
06/13/2013WO2013082915A1 Strain of exopolysaccharide-secreting lactobacillus brevis and application thereof
06/13/2013WO2013082839A1 Drug-loaded liposome for overcoming tumor drug resistance, method for preparing same, and application thereof
06/13/2013WO2013082756A1 Phosphate transport inhibitors ii
06/13/2013WO2013082751A1 Phosphate transport inhibitors i
06/13/2013WO2013082706A1 Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing
06/13/2013WO2013082656A1 Cage amine ligands for metallo-radiopharmaceuticals
06/13/2013WO2013063679A8 Use of neu1 sialidase inhibitors in the treatment of cancer
06/13/2013WO2013059634A9 Use of cdk9 inhibitors to reduce cartilage degradation
06/13/2013WO2013058631A3 Diterpene furanoids compound which inhibits protein tyrosine phosphatase 1b and the use thereof
06/13/2013WO2013058613A3 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient
06/13/2013WO2013058511A3 Method for preparing high-purity montelukast sodium salt
06/13/2013WO2013057592A3 Treatment of sickle cell disease
06/13/2013WO2013057570A3 Acrylic polymer formulations
06/13/2013WO2013056684A3 Thiazole derivative as dhodh inhibitor and use thereof
06/13/2013WO2013056132A3 Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
1 ... 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 ... 7860